Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    In a World Where You Can Be Anything, Be Kind
    Nurse staffing
    In a World Where You Can Be Anything, Be Kind
    December 11, 2020
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    Access to cancer care
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    December 04, 2020
    Why All Oncology Nurses Should Be Environmentalists
    Oncology nurse influence
    Why All Oncology Nurses Should Be Environmentalists
    November 27, 2020
    ELNEC Milestone Marks Transformation of EOL Care for Countless Patients With Cancer
    Oncology nurse education
    ELNEC Milestone Marks Transformation of EOL Care for Countless Patients With Cancer
    November 20, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    Care Delivery Models Guide Cancer Practice During COVID-19
    COVID-19

    Care Delivery Models Guide Cancer Practice During COVID-19

    Healthcare institutions have used care delivery models to guide practice for years. A care delivery model provides a structured system for work assignments, responsibilities, and authority to provide optimal patient care.

    July 10, 2020
    Myeloproliferative Neoplasm Symptoms, Diagnosis, Treatment, and Survivorship Recommendations
    Survivorship

    Myeloproliferative Neoplasm Symptoms, Diagnosis, Treatment, and Survivorship Recommendations

    Myeloproliferative neoplasms are a group of blood cancers that start with a small mutation in the stem cells of the bone marrow. Although MPNs are quite rare, essential thrombocythemia, polycythemia vera, and myelofibrosis are the most common types. Each represents a mutation of a different source of stem cell.

    July 09, 2020
    FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
    U.S. Food and Drug Administration (FDA)

    FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes

    On July 7, 2020, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine (Inqovi®) for adult patients with myelodysplastic syndromes, including the following:

    July 08, 2020
    How to Approach Medical Device Failures
    Oncology nurse education

    When Function Becomes Malfunction

    Malfunctioning medical products can pose safety risks to both patients and nurses and waste valuable time and resources. All medical devices and equipment used in the United States must pass specific manufacturing requirements before they can be approved for sale. But every product, regardless of performance, is subject to malfunction. A challenge for nurses is determining whether an issue is a rare failure or if the product is legitimately problematic.

    July 07, 2020
    FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment
    Oncology drug research

    FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment

    On June 30, 2020, the U.S. Food and Drug Administration (FDA) approved avelumab (Bavencio®) for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

    July 02, 2020
    Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment
    Cancer research

    Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment

    A new class of drugs, antibody-drug conjugates (ADCs), combines the specificity of targeted therapy with the cytotoxicity of chemotherapy for a powerhouse effect against certain types of cancer variants. Here’s what you need to know about this novel treatment modality.

    July 01, 2020
    FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer

    On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

    June 30, 2020
    FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf for HER2-Positive Breast Cancer
    Oncology drug research

    FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf for HER2-Positive Breast Cancer

    On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo™) via subcutaneous injection for use in combination with docetaxel to treat patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

    June 30, 2020
    Develop Your Individual Cancer Screening Plan
    Cancer screening

    Develop Your Individual Cancer Screening Plan

    As oncology nurses, we know that catching cancer early through screening leads to better outcomes and increased survival rates. We ask our survivors and loved ones to prioritize their cancer screenings, reminding them, “I do not want to see you in my clinic chair or hospital bed with cancer, especially not at an advanced level.” Take care of yourself by giving yourself the same lecture.

    June 29, 2020
    FDA Approves Pembrolizumab for Treatment of Cutaneous Squamous Cell Carcinoma
    Oncology drug research

    FDA Approves Pembrolizumab for Treatment of Cutaneous Squamous Cell Carcinoma

    On June 24, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable with surgery or radiation.

    June 25, 2020
    Cancer Consortium Report Reveals High Mortality Rates in Patients With COVID-19 and Cancer
    COVID-19

    Cancer Consortium Report Reveals High Mortality Rates in Patients With COVID-19 and Cancer

    Patients with cancer who contracted the COVID-19 coronavirus had high rates of 30-day all-cause mortality that was associated with general risk factors and risk factors unique to cancer, according to findings from one of the first data registry reports of patients with the dual diagnoses. The results were published in Lancet.

    June 25, 2020
    Nurses Can Provide Safe Spaces for LGBTQ Patients With Cancer
    Patient advocacy

    Nurses Can Provide Safe Spaces for LGBTQ Patients With Cancer

    The 2019–2022 ONS Research Agenda mentions LGBTQ patients with cancer among ONS’s research priorities for the very first time. A panel discussion at the 44th Annual ONS Congress focused on this underrepresented patient population, so we are making progress. In the past few years, our field has given a little more attention to LGBTQ patients with cancer, although I suspect that many of the issues are still pervasive.

    June 24, 2020
    FDA Approves Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Oncology drug research

    FDA Approves Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    On June 22, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio®) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

    June 23, 2020
    FDA Grants Accelerated Approval to Tazemetostat for Follicular Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Tazemetostat for Follicular Lymphoma

    On June 18, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik™), an EZH2 inhibitor, for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, who have received at least two prior systemic therapies and have no satisfactory alternative treatment options.

    June 19, 2020
    Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization
    Chemotherapy

    Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization

    Patients who take five or more medications in the six months before beginning IV chemotherapy for a cancer diagnosis are more likely to be hospitalized after their chemotherapy treatment, according to the findings from a new study published in the Journal of Geriatric Oncology.

    June 19, 2020
    FDA Approves Pembrolizumab for Patients With TMB-H Solid Tumors
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for Patients With TMB-H Solid Tumors

    On June 16, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda®) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and have no satisfactory alternative treatment options.

    June 17, 2020
    Misconceptions About Radioactive Targeted Therapies
    Genetics & genomics

    An Oncology Nurse’s Primer on Genomics and Biomarker Terminology

    With the massive paradigm shift in cancer therapy to precision medicine, the use of biomarkers and biomarker testing has also rapidly evolved to guide treatment selection. However, the terminology used in genomics is complex and inconsistent, and patient advocacy organizations recommend using a common taxonomy to prevent confusion among patients and providers alike. Nurses spend more time with patients and families than any other member of the healthcare team and can reinforce common language and terminology. As a nurse, here are the terms you need to understand.

    June 17, 2020
    Exercise Before ADT Treatment Reduces Rate of Side Effects
    Cancer research

    Exercise Before ADT Treatment Reduces Rate of Side Effects

    Beginning a supervised exercise program before the start of androgen deprivation therapy (ADT) for prostate cancer reduced the incidence of treatment-related side effects, researchers reported in a study published in BJU International.

    June 17, 2020
    FDA Extends Indication for Gemtuzumab Ozogamicin for CD33-Positive AML in Pediatric Patients
    U.S. Food and Drug Administration (FDA)

    FDA Extends Indication for Gemtuzumab Ozogamicin for CD33-Positive AML in Pediatric Patients

    On June 16, 2020, the U.S. Food and Drug Administration (FDA) extended the indication of gemtuzumab ozogamicin (Mylotarg™) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients aged 1 month and older.

    June 16, 2020
    FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer

    On June 15, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin (Zepzelca™) for adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.

    June 16, 2020
    Pelvic Radiation May Decrease Bone Mineral Density
    Radiation therapy

    Pelvic Radiation May Decrease Bone Mineral Density

    Women receiving pelvic radiation therapy for gynecologic cancers are at higher risk for significant decreases in bone mineral density (BMD), with 7.8% of women in the study diagnosed with a pelvic fracture, according to findings from a study published in Cancer.

    June 10, 2020
    Manage Late Effects From HPV-Positive Oropharyngeal Cancers
    Late effects

    Manage Late Effects From HPV-Positive Oropharyngeal Cancers

    The demographic of patients with oropharyngeal cancers is changing. Clinicians are diagnosing fewer older patients with a long history of heavy smoking and alcohol use; instead, a majority of patients are middle-aged Caucasian men who haven’t smoked but have had multiple sexual partners—and have tested positive for human papillomavirus.

    June 09, 2020
    Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations
    Clinical practice

    Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations

    Multiple myeloma is a plasma cell neoplasm and the second most common hematologic malignancy in the United States, although overall incidence rates are relatively low at approximately 32,000 annually. The overall five-year survival rate is 52%, and most people are diagnosed with the disease in later stages.

    June 09, 2020
    How Nurses Can ‘Curb the Spread’ and Support Themselves
    COVID-19

    How Nurses Can ‘Curb the Spread’ and Support Themselves

    As the United States reopens and social distancing moves into different phases, concerns remain about containing the COVID-19 coronavirus. Anxiety and stress are high as nurses and other healthcare professionals who are caring for COVID-19 positive patients are worried about their own health and the health of their families. A paramount fear is inadvertently spreading the virus to ourselves or our loved ones.

    June 05, 2020
    E-Cigarettes Linked to Bladder Cancer Carcinogens
    Cancer research

    E-Cigarettes Linked to Bladder Cancer Carcinogens

    People who use e-cigarettes have six substances that have a strong link to bladder cancer in their urine, researchers reported in European Urology Oncology.

    June 03, 2020
    Nursing Considerations to Reduce Barriers to Care
    Cancer health disparities

    LGBTQ Patients With Cancer

    Recognized by the National Academies of Medicine as a population vulnerable to health disparities, people who identify as lesbian, gay, bisexual, transgender, or queer (LGBTQ) experience specific health disparities, including limited access to health care, increased risk for certain disease types, and an inherent bias in the health system.

    June 02, 2020
    FDA Approves Ramucirumab Plus Erlotinib for First-Line Treatment of Metastatic NSCLC
    Oncology drug research

    FDA Approves Ramucirumab Plus Erlotinib for First-Line Treatment of Metastatic NSCLC

    On May 29, 2020, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza®) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 mutations. 

    June 01, 2020
    FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC
    Oncology drug research

    FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC

    On May 26, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab plus ipilimumab  and two cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.

    May 27, 2020
    FDA Approves Brigatinib for ALK-Positive, Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Brigatinib for ALK-Positive, Metastatic NSCLC

    On May 22, 2020, the U.S. Food and Drug Administration (FDA) approved brigatinib (Alunbrig®) for adult patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC). FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion diagnostic for brigatinib. 

    May 26, 2020
    FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer
    Oncology drug research

    FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer

    On May 19, 2020, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza®) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated, metastatic, castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

    May 20, 2020
    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression

    On May 18, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) for first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining ≥ 50% of tumor cells [TC] or PD-L1-stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area), with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. 

    May 19, 2020
    FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumor
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumor

    On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved ripretinib (Qinlock™) for adult patients with advanced gastrointestinal stromal tumors (GISTs) who received prior treatment with three or more kinase inhibitors, including imatinib. 

    May 18, 2020
    FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated, Metastatic, Castration-Resistant Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated, Metastatic, Castration-Resistant Prostate Cancer

    On May 15, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca®) for patients with deleterious BRCA mutation (germline or somatic)-associated, metastatic, castration-resistant prostate cancer (mCRPC) who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. 

    May 18, 2020
    FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer

    On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥ 1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. 

    May 18, 2020
    FDA Grants Accelerated Approval to Pomalidomide for Kaposi Sarcoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Pomalidomide for Kaposi Sarcoma

    On May 14, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of pomalidomide (Pomalyst®) to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV negative. 

    May 15, 2020
    COVID-19 patient education
    Clinical practice

    COVID-19 Talking Points for Patients With Cancer, Caregivers, and Family Members

    To keep our communities safe and the most vulnerable people healthy, everyone needs to stay at home as much as possible. But patients with cancer and survivors must take extra steps to help maintain their health and safety. These patient education talking points can help people with cancer, as well as their family members and caregivers, stay well while staying at home.

    May 12, 2020
    How to Prevent Opioid Misuse While Effectively Managing Cancer Pain
    Pain management

    How to Prevent Opioid Misuse While Effectively Managing Cancer Pain

    Opioid misuse is prevalent among the U.S. population—so much so that President Trump declared it a public health emergency in 2017. At the same time, research shows that 20%–50% of patients with cancer and 80% of those with advanced-stage disease report experiencing moderate to severe pain. Balancing the dichotomies is difficult, but oncology nurses and other cancer care providers have a responsibility to provide comprehensive pain management for patients with cancer.

    May 12, 2020
    Remodeled CAR T-Cell Therapy May Reduce Side Effects
    Cancer treatments

    Remodeled CAR T-Cell Therapy May Reduce Side Effects

    A new type of remodeled CAR T-cell treatment is just as effective as the original therapy but may result in fewer neurologic side effects, researchers reported in Nature Medicine.

    May 06, 2020
    Harnessing the Abscopal Effect May Change Cancer Care
    Radiation therapy

    Harnessing the Abscopal Effect May Change Cancer Care

    The abscopal effect is a unique phenomenon in cancer treatment that occurs when radiation shrinks untreated tumors found elsewhere in the body in addition to the targeted tumor. The effect has a long history, dating back to the 1950s, but it doesn’t commonly occur in practice and the mechanisms are not fully understood. Research has shown that combining immunotherapy with radiation increases the rate at which the abscopal effect occurs. Understanding how it appears in practice could potentially lead to new cancer treatments and a novel approach to combining immunotherapies with radiation.

    May 05, 2020
    The Next Frontier for Oncology Nursing Care
    Immunotherapy

    Combination Immunotherapy

    Immunotherapies have revolutionized the approach to cancer treatment by leveraging patients’ own immune systems to fight the disease. But the novel therapies have also brought an evolution in traditional treatment regimens through their combination with chemotherapy, radiation, targeted therapy, or even other immunotherapy drugs.

    May 05, 2020
    Drug Combo May Be Effective for BRCA-Mutated Pancreatic Cancer
    Pancreatic cancer

    Drug Combo May Be Effective for BRCA-Mutated Pancreatic Cancer

    More than 65% of patients with germline BRCA/PALB2-mutated pancreatic ductal adenocarcinoma responded to treatment with combination cisplatin and gemcitabine, according to results of a study reported in the Journal of Clinical Oncology. Two- and three-year survival rates reached 31% and 18%, respectively.  

    April 22, 2020
    What Happens During a Genetics Counseling Session?
    Genetics & genomics

    What Happens During a Genetics Counseling Session?

    When referring patients for genetics counseling and possible testing for hereditary risk, oncology nurses can help relieve their trepidation and anxiety by explaining what to expect during the visit. See the sidebar for key indications for referral.

    March 26, 2020
    Proper PPE Procedures for COVID-19
    COVID-19

    Proper PPE Procedures for COVID-19

    Although many oncology nurses are well versed in donning and doffing (removal) of personal protective equipment (PPE) for administering hazardous drugs, but not infection control. Additionally, nursing colleagues in other specialties may not wear PPE as part of their daily practice. As the COVID-19 novel coronavirus pandemic changes that, oncology nurses should understand PPE use for infection control to promote safety for nurses and patients.   

    March 17, 2020
    Emotional Coping Strategies for COVID-19
    Clinical practice

    Emotional Coping Strategies for COVID-19

    The COVID-19 novel coronavirus pandemic is turning the world, inside and outside of the hospital, upside down. Not only are oncology nurses seeing high demands at work, but changes and restrictions are being instated at home as well.

    March 16, 2020
    U.S. Still Has Declining Cancer Death Rates, Latest National Report Says
    Research

    U.S. Still Has Declining Cancer Death Rates, Latest National Report Says

    Overall cancer death rates fell 1.5% on average per year from 2001–2017 in the United States for all cancer sites combined, according to the Annual Report to the Nation on the Status of Cancer from the Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), American Cancer Society, and North American Association of Central Cancer Registries.

    March 16, 2020
    Telehealth Visits During COVID-19
    Clinical practice

    Telehealth Visits During COVID-19

    With the Centers for Disease Control and Prevention’s recommendations for practicing social distancing to slow the national risk of transmission of COVID-19 novel coronavirus, oncology nurses must take increased precautions with patients with cancer who are at increased risk for contracting or experiencing poorer outcomes from COVID-19. Patients require communication and education in these uncertain times.

    March 13, 2020
    COVID-19 Telephone Triage for Patients With Cancer
    Clinical practice

    COVID-19 Telephone Triage for Patients With Cancer

    During the COVID-19 novel coronavirus pandemic, patients might be fearful and uncertain if they should come to their clinic appointments. COVID-19 presents greater risks to older adults and people with comorbid diseases such as cancer and other chronic conditions, and patient concerns will likely increase the volume of phone calls into your clinics and telephone triage lines. Oncology nurses can use the opportunity to assess and educate patients.

    March 13, 2020
    NIDA Calls for Further Cannabis Research in Congress Testimony
    Health Policy

    NIDA Calls for Further Cannabis Research in Congress Testimony

    Medical cannabis has been approved for use in more than 33 states, many of which have decriminalized its use as well, and a health policy wave has spread across the country through state referendums to ease the burden for legalizing cannabis for health purposes. It’s a different world than it was 30 years ago, and the National Institute on Drug Abuse (NIDA) is frequently called to testify before Congress to address concerns and questions from lawmakers.

    March 12, 2020
    BD Issues Class I Recall of Alaris System Infusion Pumps
    U.S. Food and Drug Administration (FDA)

    BD Issues Class I Recall of Alaris System Infusion Pumps

    On February 4, 2020, BD announced a recall of all lots of affected models of its Alaris System pump modules because of multiple system errors, software errors, and use-related errors. On March 6, 2020, the U.S. Food and Drug Administration identified it as a class I recall, its most serious level of recalls, because of the possibility of serious injuries or death.

    March 10, 2020
    COVID-19 Fact Sheet and Implications for Patients With Cancer
    Clinical practice

    COVID-19 Fact Sheet and Implications for Patients With Cancer

    COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in Wuhan, China, in December 2019. It is a respiratory illness and can be spread from person to person, possibly through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

    March 04, 2020
    • First page « First
    • Previous page
    • Page 1
    • Current page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲